- Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment2015 | Farmaceutická fakulta v Hradci Králové
- Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics2006 | Farmaceutická fakulta v Hradci Králové
- IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors2016 | Přírodovědecká fakulta
- Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-292011 | Farmaceutická fakulta v Hradci Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Farmaceutická fakulta v Hradci Králové
- Purification and characterization of an oxidoreductase in human liver cytosol participating in carbonyl reduction of the tobacco-specific nitrosamine NNKPublikace bez příslušnosti k fakultě
- Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro2013 | Farmaceutická fakulta v Hradci Králové
- Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes2017 | Farmaceutická fakulta v Hradci Králové
- Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier2015 | Farmaceutická fakulta v Hradci Králové
- Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?2020 | Farmaceutická fakulta v Hradci Králové
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C32019 | Farmaceutická fakulta v Hradci Králové